Shanghai Fosun Pharmaceutical (SHA:600196) obtained a drug registration for monoclonal antibody injection HLX11 from China's drug administrator.
HLX11 is a pertuzumab biosimilar intended to be used in combination with trastuzumab and chemotherapy for the treatment of breast cancer, according to a Wednesday filing with the Shanghai Stock Exchange.
Shares of the pharmaceutical company were down 1% in recent trade
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments